Following the revelation of a $2.2 billion settlement pertaining to US lawsuits claiming that GSK’s discontinued heartburn treatment, Zantac, caused cancer, the company’s shares (GSK.L) shot up as much as 6.5% on Thursday. The settlement was much smaller than expected; JP Morgan had previously estimated that it might have cost $3.5 billion. The deal was … Continue reading After The $2.2 Billion Settlement Deal, GSK Shares Surge.